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Abstract
Elevated expression of the drug efflux transporter ABCG2 seems to correlate with 
multidrug resistance of cancer cells. Specific COX-2 inhibitor celecoxib has been shown 
to enhance the sensitivity of cancer cells to anticancer drugs. To clarify whether ABCG2 
inhibition is involved in the sensitizing effect of celecoxib, we investigated whether the 
expression of ABCG2 in breast cancer cell lines could be modulated by celecoxib. The 
expression of the multidrug resistant gene (ABCG2) at mRNA and protein level was 
detected by real-time quantitative reverse transcription-polymerase chain reaction and flow 
cytometry analysis, respectively. Among three human breast cancer cell lines, ABCG2 and 
COX-2 were highly expressed in MCF7-MX and MDA-MB-231 cells, respectively. The 
COX-2 inhibitor celecoxib up-regulated the expression of ABCG2 mRNA in MCF-7 and 
MCF7-MX cells, which was accompanied by increased ABCG2 protein expression. While 
celecoxib was able to block the 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated 
increase in COX-2 expression in MDA-MB-231 cells, it increased the expression of ABCG2 
up to 4.27 times to the control level at mRNA level and with less intensity at protein level. 
Our findings provide evidence that celecoxib up-regulates ABCG2 expression in human 
breast cancer cells and proposed that ABCG2 is not involved in chemosensitizing effects of 
celecoxib.
Keywords: Multidrug resistance; ATP-binding cassette transporter; ABCG2; MCF-7; 
Celecoxib.
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Introduction
Cyclooxygenases-2 (COX-2) plays an 
important role in the prostaglandins production 
involved in pathophysiological processes 
like inflammation and carcinogenesis (1, 2). 
COX-2 has been characterized as a critical 
prognostic factor in numerous solid tumors (3). 
Numerous studies showed that specific COX-
2 inhibitors (coxibs) enhance the efficacy of 
different anticancer therapy methods through 
inhibition of cell cycle progression, induction 
of apoptosis, inhibition of angiogenesis and 
decreased invasive potential of tumor cells (4-6). 
Another mechanism by which COX-2 inhibitors 
could sensitize cells to chemotherapeutic drugs 
is functional blockade of membrane transporter 
proteins of the ATP binding cassette transporter 
(ABC-transporter) family (7, 8).
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L-glutamine and FBS were purchased from 
Biosera (UK) and Gibco (USA), respectively.
Cell culture 
The ABCG2-overexpressing, mitoxantrone-
resistance epithelial breast cancer cell line, 
MCF-7/MX, and its parental line, MCF-7 were 
generously provided by Dr. Erasmus Schneider 
(Wadsworth Center, New York State Department 
of Health, USA) and MDA-MB-231 (COX-2 
expressing cell line) was generously provided 
by Dr. Mohammad Kazem Koohi (Faculty of 
Veterinary Medicine, university of Tehran, Iran). 
Cells were cultured in RPMI-1640, supplemented 
with 2 mM of L-glutamine, heat inactivated 
FBS 10% (v/v), penicillin (50 U/mL), and 
streptomycin (50 μg/mL) at 37 °C in humidified 
air containing CO
2 
5%. Since FBS has been 
shown to induce COX-2 (due to the presence 
of growth factors (17)), before treatment, 
subconfluent cells were washed with PBS and 
changed to serum-free medium containing BSA 
0.1% (w/v) for 24 h. Mitoxantrone (MX) (100 
nM) was added to MCF-7/MX cells to maintain 
the multidrug-resistant phenotype. MCF-7/MX 
cells were cultured on MX free for at least 7 days 
prior to experiments.
Reverse transcription-real-time polymerase 
chain reaction (RT-PCR)
Total cellular RNA was extracted using a High 
Pure RNA Isolation Kit from Roche Applied 
Science (Cat. No. 11828665001). The eluted 
RNA samples were stored at –80 °C for later 
analysis or directly used in RT-PCR. In order 
to evaluate the effects of celecoxib on ABCG2 
and COX-2 expression, comparative Ct methods 
using EXPRESS One-Step SYBR® GreenER™ 
Universal (Invitrogen) were performed and 
analyzed on a Real time cycler Mx3000P™ 
Stratagen (Stratagen, USA ). The primers 
had the following sequences: ABCG2: 5 -´ 
TATCAATGGGATCATGAAACCTGG-3  ´(forward) 
and 5´-GCGGTGCTCCATTTATCAGAAC-
3´(reverse); COX-2, 5´-AATCATTCACCAGGC
AAATTG- 3´ (forward) and 5´-TCTGTACTGCGG
GTGGAACA- 3´ (reverse ); β-actin: 5´-TCATGA
AGTGTGACGTGGACATC-3´ (forward) and 
5´-CAGGAGGAGCAATGATCTTGATCT-3´ 
(reverse). Relative mRNA levels of the target 
gene in each sample were normalized to its 
The development of intrinsic or acquired 
resistance to a wide variety of anticancer 
drugs is a major obstacle to successful cancer 
chemotherapy. One of the mechanisms by 
which human cancers develop multidrug 
resistance is the overexpression of efflux 
transport proteins on the plasma membrane 
of cancer cells. ATP-binding cassette sub-
family G member 2 (ABCG2), a novel known 
protein, is an efflux pump which transports 
a variety of xenobiotics and endogenous 
compounds across cellular membranes. 
Tissue localization of ABCG2 indicates that 
ABCG2 plays an important role in absorption, 
distribution and elimination of its substrates 
(9, 10). Alteration in ABCG2 expression and 
activity can significantly affect the disposition 
of the transporter drug substrates, so it’s over 
expression in cancer cells is responsible for 
decreasing in drug concentration within the 
cell and a reduced cancer-chemotherapy 
efficacy (9, 11). 
Previously, we showed that proinflammatory 
cytokines (IL-1β and TNF-α) significantly 
increased the levels of ABCG2 mRNA, protein 
expression and function, while dexamethasone 
(an anti-inflammatory drug) reduced its 
expression and activity (12-16). The present 
study aimed to examine the relationship 
between the inhibition of COX-2 and 
expression of ABCG2 in parental and resistant 
breast cancer cell lines. Understanding the 
relationship between COX-2 and ABCG2 
may open novel perspectives in cancer 
therapy, in which, coxibs could be employed 
as a chemotherapy-supporting treatment. 
Introducing coxibs into the treatment regimen 
will then augment efficiency of chemotherapy 
and maybe helpful in prevention or inhibition 
of the development of the multidrug resistance 
(MDR) phenomenon.
Experimental
Chemicals and antibodies
 TPA (12-O-tetradecanoylphorbol-13-
acetate), BSA and penicillin–streptomycin were 
purchased from Sigma–Aldrich (Germany). 
Celecoxib was generousely provided by 
Daru Pakhsh (Tehran, Iran). RPMI 1640 with 
Celecoxib upregulates ABCG2 expression
1395
β-actin content. The results were expressed 
as ratio of relative quantity to calibrator of the 
treated samples divided by relative quantity to 
calibrator of untreated sample.
Flow cytometric detection of COX-2 protein 
expression
For intracellular detection of COX-2 by flow 
cytometry, breast cancer cells were fixed and 
permeabilised using the Leucoperm™ fixation 
and permeabilization solution, following the 
manufacturer’s instructions (18). Thereafter, 
the cells were blocked with BSA 10 % (w/v) 
and incubated with 50 ng of Phycoerythrin (PE) 
-conjugated anti-human COX-2 for 30 min. 
Finally samples were washed, resuspended 
in PBS and analysed by PartecTM cytometer 
with 585/42 band pass filter (FL2). Relative 
expression of COX-2 was calculated, comparing 
the values of mean fluorescence intensity (MFI) 
of treated samples to the values of MFI of 
untreated sample.
 
Flow cytometric detection of ABCG2 protein 
expression
The ABCG2 protein expression was measured 
with the BXP-21 monoclonal antibodies, which 
recognize an internal epitope of the ABCG2 protein 
as we previously described (12, 14). In brief, after 
fixation and permeabilization, the cells were 
blocked with bovine serum albumin (BSA) 10% 
(w/v) for 1 h at room temperature. Thereafter, the 
cells were incubated for 60 min on ice with anti-
ABCG2 mAb BXP-21 (1:100). Cells were washed 
with phosphate buffered saline/bovine serum 
albumin and incubated on ice for 20 minutes with 
Fluorescein isothiocyanate (FITC) -conjugated 
goat anti-mouse antibody (1:50) to detect the 
primary anti-ABCG2 mAb. FITC fluorescence 
was measured on a PartecTM cytometer with 
530/30 nm band pass filter (FL1). Flow cytometry 
data were processed and analyzed using FloMax 
version 2.52 and WinMdi version 2.8 software. All 
assays were performed in at least three independent 
experiments. Relative expression of ABCG2 was 
determined as the ratio of MFI of treated samples 
divided by MFI of untreated sample.
Statistical analyses
Statistical analyses were carried out using 
SPSS 16.00 software. Results (mean ± S.D.) 
were reported as three independent experiments 
each performed in triplicate. The statistical 
significance of the results was calculated using 
multivariate analysis of variance (MANOVA) 
with Tukey’s post-hoc or Student’s t-test and 
p-values < 0.05 were considered significant.
Results
ABCG2 and COX-2 expression in MCF7 cells
In order to assess ABCG2 and COX-2 
expression in MCF7 cells, the expression of 
these two genes was evaluated in MCF7 and 
control cell lines (MCF7-MX and MDA-MB-
231cells) by real time RT-PCR. As shown in 
Figure 1, ABCG2 mRNA level in resistant cell 
line MCF7-MX was ≈ 850 and 5200 times 
more than the ABCG2 mRNA level in MCF-
7 and MDA-MB-231 cells, respectively. The 
expression of COX-2 in MDA-MB-231 cells 
was ≈ 5.5 and 9.2 times more than MCF-7 and 
MCF7-MX cells, respectively (Figure 1). These 
data are further strengthened by the results of 
flowcytometry analyses for ABCG2 and COX-2 
protein expression (data not shown).
Effects of celecoxib on COX-2 expression
To evaluate the expression of COX-2 
mRNA under celecoxib treatment, three cell 
lines were treated with non-toxic concentration 
of TPA (10 nM) and celecoxib (0-40 µM) for 
4-24 h (15). Expression of COX-2 was studied 
using Real-time RT-PCR. We have previously 
reported that TPA was a potent stimulator of 
COX-2 expression in breast cancer cell lines; 
as it stimulates COX-2 expression up to 4.5 
fold vs. control by 4 h in MDA-MB-231 cells 
(15). Figure 2 indicates that celecoxib reverses 
the effects of TPA on COX-2 expression to 
the control level in MDA-MB-231 by 4 h. 
Celecoxib significantly inhibited COX-2 
expression by 12 and 24 h in MCF-7 and by 
24 h in MCF7-MX (data not shown). To verify 
whether the inhibitory effects of celecoxib on 
COX-2 expression could be observed also in 
protein level, cells were treated for 4 and 24 h 
without or with TPA 10 nM, celecoxib 40 µM, 
or both. Then, the cells were incubated with the 
specific COX-2 antibody. As shown in Figure 3, 
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MDA-MB-231 cells treated with TPA displayed 
an increased COX-2 protein expression, which 
was significantly reduced by co-treatment with 
celecoxib.
Effects of celecoxib on ABCG2 gene 
expression
To verify whether ABCG2 gene expression 
could be influenced by incubation with 
celecoxib, real time RT-PCR analysis was 
performed on RNA from breast cancer cells 
previously treated for 4, 12 and 24 h with TPA 
10 nM in combination with celecoxib 0-40 µM. 
The results showed that celecoxib enhanced 
the effects of TPA on ABCG2 expression in 
MCF-7 and MCF7-MX. In MCF-7 (Figure 4a), 
ABCG2 expression increased up to 1.62 times 
under treatment with TPA 10 nM for 12 h while 
combination treatment with celecoxib 40 µM / 
TPA 10 nM caused up to 2.67 times increased 
in ABCG2 expression to control level in the 
same incubation time. As shown in Figure 4b, 
Figure 1. Basal expressions of ABCG2 and COX-2 mRNA in breast cancer cell lines were studied by real time RT-PCR. ABCG2 mRNA 
level is compared between drug resistant cell line MCF7-MX with MCF-7 (A) and MDA-MB-231 (B) cells. In addition, COX-2 mRNA 
level is compared between COX-2 overexpressing cell line MDA-MB-231 with MCF- 7 (C) and MCF7-MX (D). Real-time RT-PCR 
analysis was performed on total RNA extracted from cells. Values were normalized to the β-actin content of samples and expressed as 
mean ±SD (n = 3).
Figure 2. COX-2 mRNA expression in MDA-MB-231 cell line under treatment with and without celecoxib. Line chart shows the results 
of cells that were treated with TPA 10 nM lonely. Bar chart indicated the results of cells that were treated with TPA 10 nM in combination 
with celecoxib 0-40 µM for 4-24 h. Real-time RT-PCR analysis was performed on total RNA extracted from control and treated cells. 
Values were normalized to the β-actin content of samples. The results were expressed as the target/reference ratio of the treated samples 
divided by the target/reference ratio of the untreated control sample and expressed as mean ± SD (n = 3); *, p < 0.05; **, p < 0.01; ***, 
p < 0.001.
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Figure 3. COX-2 protein expression in MDA-MB-231 cell lines under treatment with TPA, and celecoxib for 4 h (A) and 24 h (B). 
Cells were treated with or without TPA 10 nM, and celecoxib 40 µM and COX-2 protein expression were measured by flow cytometric 
assay, which developed for detection of COX-2. Briefly, after fixation and permeabilization, cells were blocked with BSA 10% (w/v) 
and incubated with PE- conjugated anti-COX-2 mAbs. COX-2 protein level expressed as mean fluorescence intensity (MFI) of PE-
fluorescence of 10,000 cells that was quantified in histogram plots. Each histogram shows the overlay of the TPA treated sample (dark 
gray), TPA and celecoxib treated sample (ligh gray), untreated sample (black) and unstained control sample, which has been used to 
detect autofluorescence (broken light gray).
celecoxib 20 µM induced ABCG2 expression 
from 1.69 times (under TPA 10 nM treatment) 
to 2.29 times to control level by 4 h in MCF7-
MX cells. On the other hand, celecoxib reversed 
the TPA effects on ABCG2 expression in MDA-
MB-231 cell line. We previously reported that 
TPA significantly reduced ABCG2 expression 
to about 0.2 times to control level by 12 and 24 
h (18), while as shown in Figure 4c, celecoxib 
stimulated the expression of ABCG2 up to 4.27 
times to control level by 12 h in MDA-MB-231 
cells.
Influence of celecoxib on ABCG2 protein 
expression
In order to verify whether the observed 
effects at mRNA level were mirrored by 
parallel changes in ABCG2 protein levels, flow 
cyotmtry analysis for ABCG2 was performed 
using breast cancer cells treated for 4 and 24 
h with TPA 10 nM and celecoxib 40 µM. We 
previously showed that TPA could cause a 
small increase in ABCG2 expression in MCF-
7, on the contrary, treatment of MCF7-MX and 
MDA-MB-231 cells with TPA resulted in a small 
decrease in ABCG2 protein expression (18). As 
indicated in Figure 5, celecoxib reversed the 
inhibitory effects of TPA on ABCG2 protein 
expression and increased its expression to the 
basal level in MCF7-MX and MDA-MB-231. 
Co-treatment of MCF-7 cells with TPA and 
Celecoxib caused increased ABCG2 protein 
expression to a small amount more than TPA 
lonely (Figure 5c).
Discussion 
ABCG2 is an important member of the ABC- 
transporter family, which functions as pumps 
to extrude anticancer drugs from cancer cells, 
by this means causing MDR in cancer patients 
(9). This study tested the hypothesis that COX-
2 inhibitor celecoxib plays a role in regulating 
ABCG2 expression in human breast cancer cells. 
Recent studies indicated that the activation of 
the cyclooxygenase system is correlated with the 
increased expression of MDR1 in acute myeloid 
leukemia HL-60 cells, primary rat hepatocytes, 
renal rat mesangial cells as well as breast 
cancer patients (7, 19-21). While, selective 
COX-2 inhibitors have been shown to increase 
sensitivity of cancer cells to chemotherapy via 
reduction of drug resistance in human patients 
with AML, breast, ovarian and colon cancer (3, 
19, 22, 23). On the other hand, in this study we 
showed that celecoxib up-regulated ABCG2 
mRNA expression in drug sensitive MCF-7 cells. 
Our finding indicated that celecoxib reduced 
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Figure 4. Effects of celecoxib on the levels of ABCG2 mRNA in MCF-7 (A), MCF7-MX (B), and MDA-MB-231 (C) cell lines. 
Cells were treated for 4, 12, and 24 h with TPA 10 nM alone (line chart) or in combination with celecoxib 0-40 µM (bar chart) and 
ABCG2 mRNA expression were measured by real-time RT-PCR using total RNA extracted from control and treated cells. Values 
were normalized to the β-actin content of samples. The results were expressed as the target/reference ratio of the treated samples 
divided by the target/reference ratio of the untreated control sample and expressed as mean ± SD (n = 3); *, p < 0.05; **, p < 0.01; 
***, p < 0.001.
TPA-induced COX-2 mRNA expression at 
10 µM while treatment with celecoxib 40 
µM resulted in a significant overstimulation 
of COX-2 expression. On the other hand, 
celecoxib 40 µM inhibits TPA induced COX-2 
expression at protein level (Figure 2 and 3). Our 
results are in good agreement with Niederberger 
et al. who showed that celecoxib 1 µM slightly 
reduced the IL-1β-induced COX-2 expression 
at both mRNA and protein level but increased 
COX-2 mRNA and protein expression at 50 
µM. It has been shown that transcription factor 
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Figure 5. Effects of celecoxib on the expression of ABCG2 at protein levels in MCF7-MX (A), MDA-MB-231 (B), and MCF-7 (C) cell 
lines were studied by flow cytometry. Cells were fixed and permeabilized by formaldehyde and methanol, blocked with BSA and then 
incubated with primary monoclonal antibody BXP-21. After washing, Cells were incubated with a FITC-conjugated goat anti-mouse 
antibody. Fluorescence of 10,000 cells was quantified from histogram plots using the mean fluorescence intensity (MFI). Each histogram 
shows the overlay of the TPA treated sample (black), TPA and celecoxib treated sample (dark gray), untreated sample (ligh gray) and 
secondary antibody as negative control (broken light gray).
 
Figure 5 
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NF-κB regulates the transcription of the COX-
2 gene. On the other hand, high concentrations 
of celecoxib induced the activation of NF-
kB, so activated NF-kB would stimulate the 
transcription of NF-kB-dependent genes such as 
COX-2 (24).
In this study, we reported that treatment of 
MCF-7 ,MCF7-MX and MDA-MB-231 cells 
with specific COX-2 inhibitor celecoxib up-
regulates ABCG2 expression at both mRNA 
and protein levels. In the same way, Zrieki et 
al. showed that treatment of human colorectal 
Caco-2 cell line with COX-1/ COX-2 inhibitor 
naproxen led to an stimulation of ABCG2 
expression corresponding to the significant 
decrease of rodamine 123 (Rho123) retention 
achieved in activity study. In contrast, treatment 
with selective COX-2 inhibitors nimesulide did 
not influence the expression of ABCG2 in protein 
level (25). Another study indicated that sulindac 
induced MRP1 and MRP3 gene expression via 
a ROS-related, COX-2-independent mechanism 
in human colorectal cancer cell line HCT15 
(26). Kang et al. reported that enforced COX-
2 expression in human lung carcinoma cell line 
H460 did not cause increase in MRP1 expression, 
while the celecoxib COX-2 inhibitor reduced the 
expression and function of MRP1 protein. They 
suggested that celecoxib down-regulated MRP1 
expression with a COX-independent mechansim 
(27). In contrast, several studies have shown 
that specific COX-2 inhibitors could prevent 
or reduce the development of chemoresistance 
phenotype by downregulation of the expression 
and activity of P-glycoprotein (MDR1) (8, 26, 
28-30). These inconsistencies may be due to the 
diversity among species, tissue origins, or cell 
types. 
In conclusion, our findings provide evidence 
that selective COX-2 inhibitor celecoxib 
induces ABCG2 mRNA and protein expression 
in the sensitive and drug resistant MCF7 breast 
cancer cell lines. These data may indicate a 
possible COX-2 independent mechanism for 
the stimulatory effect of celecoxib on ABCG2. 
Further studies are needed to determine whether 
other COX-2 selective inhibitors will show the 
similar effects to celecoxib and to clarify the 
molecular mechanism by which they induce 
ABCG2 expression.
Acknowledgments
The authors are indebted to the Research 
Council of Mashhad University of Medical 
Sciences, Iran, for approval and financial support 
of this project.
References
Trebino CE, Stock JL, Gibbons CP, Naiman BM, 
Wachtmann TS, Umland JP, Pandher K, Lapointe JM, 
Saha S, Roach ML, Carter D, Thomas NA, Durtschi 
BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty 
TJ, Perez JR and Audoly LP. Impaired inflammatory 
and pain responses in mice lacking an inducible 
prostaglandin E synthase. Proc. Natl. Acad. Sci. USA 
(2003) 100: 9044-9049.
Razmi A, Zarghi A, Arfaee S, Naderi N and Faizi* M. 
Evaluation of Anti-nociceptive and Anti-inflammatory 
Activities of Novel Chalcone Derivatives. Iran. J. 
Pharm. Res. (2013) 12: 153-159.
Surowiak P, Materna V, Matkowski R, Szczuraszek K, 
Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert 
C, Zabel M and Lage H. Relationship between the 
expression of cyclooxygenase 2 and MDR1/P-
glycoprotein in invasive breast cancers and their 
prognostic significance. Breast Cancer Res. (2005) 7: 
862-870.
Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka 
K, Noguchi K and Sakurai K. Apoptosis induction 
and enhancement of cytotoxicity of anticancer drugs 
by celecoxib, a selective cyclooxygenase-2 inhibitor, 
in human head and neck carcinoma cell lines. Int. J. 
Oncol. (2003) 23: 665-672.
Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle 
SL, Woerner BM, Edwards DA, Flickinger AG, Moore 
RJ and Seibert K. Antiangiogenic and antitumor 
activities of cyclooxygenase-2 inhibitors. Cancer Res. 
(2000) 60: 1306-1311.
Gasparini G, Longo R, Sarmiento R and Morabito 
A. Inhibitors of cyclo-oxygenase 2: a new class of 
anticancer agents? Lancet Oncol. (2003) 4: 605-615.
Patel VA, Dunn MJ and Sorokin A. Regulation of 
MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. 
Biol. Chem. (2002) 277: 38915-38920.
Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni 
A, Vignali C, Bondanelli M and degli Uberti EC. 
Cyclooxygenase-2 inhibitors reverse chemoresistance 
phenotype in medullary thyroid carcinoma by a 
permeability glycoprotein-mediated mechanism. J. 
Clin. Endocrinol. Metab. (2005) 90: 5754-5760.
Mao Q and Unadkat JD. Role of the breast cancer 
resistance protein (ABCG2) in drug transport. Aaps. J. 
(2005) 7: 118-133.
Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell 
K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP 
and Schuetz JD. The stem cell marker Bcrp/ABCG2 
enhances hypoxic cell survival through interactions 
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
Celecoxib upregulates ABCG2 expression
1401
This article is available online at http://www.ijpr.ir
resistance possible? Anticancer Res. (2001) 21: 2141-
2147.
Raspollini MR, Amunni G, Villanucci A, Boddi V and 
Taddei GL. Increased cyclooxygenase-2 (COX-2) and 
P-glycoprotein-170 (MDR1) expression is associated 
with chemotherapy resistance and poor prognosis. 
Analysis in ovarian carcinoma patients with low and 
high survival. Int. J. Gynecol. Cancer (2005) 15: 255-
260.
Saikawa Y, Sugiura T, Toriumi F, Kubota T, Suganuma 
K, Isshiki S, Otani Y, Kumai K and Kitajima M. 
Cyclooxygenase-2 gene induction causes CDDP 
resistance in colon cancer cell line, HCT-15. Anticancer 
Res. (2004) 24: 2723-2728.
Niederberger E, Tegeder I, Vetter G, Schmidtko A, 
Schmidt H, Euchenhofer C, Brautigam L, Grosch S and 
Geisslinger G. Celecoxib loses its anti-inflammatory 
efficacy at high doses through activation of NF-
kappaB. Faseb. J. (2001) 15: 1622-1624.
Zrieki A, Farinotti R and Buyse M. Cyclooxygenase 
inhibitors down regulate P-glycoprotein in human 
colorectal Caco-2 cell line. Pharm. Res. (2008) 25: 
1991-2001.
Kim SK, Lim SY, Wang KC, Kim YY, Chi JG, 
Choi YL, Shin HJ and Cho BK. Overexpression of 
cyclooxygenase-2 in childhood ependymomas: role of 
COX-2 inhibitor in growth and multi-drug resistance 
in-vitro. Oncol Rep. (2004) 12: 403-409.
Kang HK, Lee E, Pyo H and Lim SJ. Cyclooxygenase-
independent down-regulation of multidrug resistance-
associated protein-1 expression by celecoxib in human 
lung cancer cells. Mol. Cancer Ther. (2005) 4: 1358-
1363.
Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin 
D, Bondanelli M, Rossi R and degli Uberti EC. 
Cyclooxygenase-2 inhibitors prevent the development 
of chemoresistance phenotype in a breast cancer cell 
line by inhibiting glycoprotein p-170 expression. 
Endocr. Relat. Cancer. (2007) 14: 1029-1038.
Huang L, Wang C, Zheng W, Liu R, Yang J and 
Tang C. Effects of celecoxib on the reversal of 
multidrug resistance in human gastric carcinoma 
by downregulation of the expression and activity of 
P-glycoprotein. Anticancer Drugs (2007) 18: 1075-
1080.
Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari 
C, Vali S and Reddanna P. Celecoxib inhibits MDR1 
expression through COX-2-dependent mechanism in 
human hepatocellular carcinoma (HepG2) cell line. 
Cancer Chemother. Pharmacol. (2010) 65: 903-911.
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
with heme. J. Biol. Chem. (2004) 279: 24218-24225.
Sarkadi B, Ozvegy-Laczka C, Nemet K and Varadi 
A. ABCG2 - a transporter for all seasons. FEBS Lett. 
(2004) 567: 116-120.
Mosaffa F, Lage H, Afshari JT and Behravan J. 
Interleukin-1 beta and tumor necrosis factor-alpha 
increase ABCG2 expression in MCF-7 breast 
carcinoma cell line and its mitoxantrone-resistant 
derivative, MCF-7/MX. Inflamm Res. (2009) 58: 669-
676.
Mosaffa F, Kalalinia F, Parhiz BH and Behravan 
J. Tumor Necrosis Factor Alpha Induces Stronger 
Cytotoxicity in ABCG2-Overexpressing Resistant 
Breast Cancer Cells Compared with Their Drug-
Sensitive Parental Line. DNA Cell Biol. (2011).
Elahian F, Kalalinia F and Behravan J. Dexamethasone 
downregulates BCRP mRNA and protein expression in 
breast cancer cell lines. Oncol Res. (2009) 18: 9-15.
Kalalinia F, Elahian F and Behravan J. Potential role 
of cyclooxygenase-2 on the regulation of the drug 
efflux transporter ABCG2 in breast cancer cell lines. J. 
Cancer Res. Clin. Oncol. (2011) 137: 321-330.
Elahian F, Kalalinia F and Behravan J. Evaluation of 
indomethacin and dexamethasone effects on BCRP-
mediated drug resistance in MCF-7 parental and 
resistant cell lines. Drug Chem. Toxicol. (2010) 33: 
113-119.
Shen SC, Ko CH, Hsu KC and Chen YC. 3-OH 
flavone inhibition of epidermal growth factor-induced 
proliferaton through blocking prostaglandin E2 
production. Int. J. Cancer. (2004) 108: 502-510.
Kalalinia F, Elahian F, Hassani M, Kasaeeian J 
and Behravan J. Phorbol Ester TPA Modulates 
Chemoresistance in the Drug Sensitive Breast Cancer 
Cell Line MCF-7 by Inducing Expression of Drug 
Efflux Transporter ABCG2. Asian Pac. J. Cancer 
Prev. (2012) 13: 2979-2984.
Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, 
Schaefer D, Langebrake C, Schuermann P, Creutzig 
U and Reinhardt D. Impact of the cyclooxygenase 
system on doxorubicin-induced functional multidrug 
resistance 1 overexpression and doxorubicin sensitivity 
in acute myeloid leukemic HL-60 cells. J. Pharmacol. 
Exp. Ther. (2005) 312: 346-354.
Ziemann C, Schafer D, Rudell G, Kahl GF and Hirsch-
Ernst KI. The cyclooxygenase system participates 
in functional mdr1b overexpression in primary rat 
hepatocyte cultures. Hepatol. (2002) 35: 579-588.
Ratnasinghe D, Daschner PJ, Anver MR, 
Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA. 
Cyclooxygenase-2, P-glycoprotein-170 and drug 
resistance; is chemoprevention against multidrug 
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
or
 http:// ijpr.sbmu.ac.ir
Tell us if we are wrong? 
Visit http://www.ijpr.ir
